Frederick Locke, MD of Moffit Cancer Center and Robert Figlin, MD of Cedars-Sinai discuss ZUMA-7, the role of CAR-T in the management of relapsed/refr...

Frederick Locke, MD and Robert Figlin, MD discuss ZUMA-7 and when to start thinking about integrating CAR-T into B-cell lymphoma treatment algorithms, the role of BMT in these patients, and how recent data presented at ASH ’21 shows that CAR-T cell therapies can work well in relapsed/refractory B-cell lymphoma.